This video is under embargo. Please login to access this video.
Caption
Model simulation (100 days) of an extremely low dose of pritelivir (5 mg daily), which exerts almost no effect on viral growth. The bottom left panel is a map of the human genital tract divided into 200 regions, showing the density of protective T cells within each region. The bottom right panel is the effective reproductive number within each model region: areas where the virus is rapidly eliminated are grey or black, while areas where the virus is growing are green. As the simulation progresses, large episodes eventually occur (at day 118 and 348) because large portions of the genital tract are left unprotected These episodes are represented with the red line in the upper left panel showing viral level, and regions of the map in the upper right panel with viral load. This material relates to a paper that appeared in the 3 February 2016, issue of Science Translational Medicine, published by AAAS. The paper, by J.T. Schiffer at University of Washington in Seattle, WA, and colleagues was titled, "Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial outcomes."
Credit
J.T. Schiffer et al., <i>Science Translational Medicine</i> (2016)
Usage Restrictions
Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.